Target therapy forBRAFmutated anaplastic thyroid cancer: a clinical and molecular study
Authors' conclusion
Our results show a significant real-world efficacy of Dabrafenib plus Trametinib in both survival and recurrence compared with standard treatment, with a good safety profile.
Study context
- Population
- Anaplastic thyroid carcinoma (ATC) patients assessed for BRAF status, treated May 2018–April 2022 in a tertiary referral center
- Participants
- 27 patients
- Exposure
- Dabrafenib plus Trametinib vs multimodal therapy vs compassionate care
- DTn = 9
- Multimodal therapy (MT)n = 8reference
- Compassionate care (CC)n = 10reference
- Outcome
- Median OS
Methodological detailssingle-centre, tertiary referral center, Response assessed monthly in first 6 months, then every 3 months, by RECIST 1.1, overall survival (OS) and progression-free survival (PFS) estimated by Kaplan-Meier, compared by log-rank test
- Single-centre
- Tertiary referral center
- Response assessed monthly in first 6 months, then every 3 months, by RECIST 1.1
- OS and PFS estimated by Kaplan-Meier, compared by log-rank test
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | DT | P value |
|---|---|---|
| Alive at 12 months | 71% | |
| Median PFSDT vs BRAF WT · BRAF WT median PFS less than 32 days | median 270 days | P < 0.001 |
Alive at 12 months
- Only patients in the DT group were alive at 12 months
Molecular profiling of clinical progressions (DT)
- Pathogenic NRAS mutation found in clinical progressions
- 1 of 4
Safety
- No severe adverse events were reported
Original publication
Target therapy forBRAFmutated anaplastic thyroid cancer: a clinical and molecular study. Eur J Endocrinol. Published 10 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →